



**Australian Government**  
**Repatriation Medical Authority**

**Amendment Statement of Principles**  
**concerning**  
**DIABETES MELLITUS**  
**(Reasonable Hypothesis)**  
**(No. 83 of 2021)**

---

The Repatriation Medical Authority determines the following Amendment Statement of Principles under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

Dated 25 June 2021

The Common Seal of the  
Repatriation Medical Authority  
was affixed to this instrument  
at the direction of:

Professor Nicholas Saunders AO  
Chairperson

# Contents

1	Name.....	3
2	Commencement .....	3
3	Authority.....	3
4	Amendment.....	3

## 1 Name

This is the Amendment Statement of Principles concerning *diabetes mellitus (Reasonable Hypothesis)* (No. 83 of 2021).

## 2 Commencement

This instrument commences on 26 July 2021.

## 3 Authority

This instrument is made under subsections 196B(2) and (8) of the *Veterans' Entitlements Act 1986*.

## 4 Amendment

The Statement of Principles concerning *diabetes mellitus (Reasonable Hypothesis)* (No. 48 of 2020) (Federal Register of Legislation No. F2020L00823) is amended in the following manner:

Section	Amendment
9(6)(g)	<p><i>Replace the existing factor in paragraph 9(6)(g) with the following:</i></p> <p>taking an immune checkpoint inhibitor or an interferon within the one year before the clinical onset of diabetes mellitus;</p> <p>Note: Examples of immune checkpoint inhibitors include ipilumab, tremelimumab, nivolumab and pembrolizumab.</p>
9(6)(h)	<p><i>Delete the existing note to paragraph 9(6)(h).</i></p>
9(13a)	<p><i>Insert the following new factor at subsection 9(13a):</i></p> <p>taking an immune checkpoint inhibitor or an interferon within the one year before the clinical worsening of diabetes mellitus;</p> <p>Note: Examples of immune checkpoint inhibitors include ipilumab, tremelimumab, nivolumab and pembrolizumab.</p>
Schedule 1 – Dictionary	<p><i>Delete the existing definition of <b>having infection with a Coxsackie B virus</b>.</i></p>